Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Program Description

The treatment of HR+/HER2-negative (HER2−) metastatic breast cancer (mBC) is rapidly changing with innovative targeted therapies. These novel therapies require careful consideration of dosing variations, administration schedules, and potential adverse effects (AEs). While offering significant clinical benefit, novel therapies such as CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT inhibitors, oral selective estrogen receptor degraders, and antibody-drug conjugates, are associated with unique and potentially serious AEs, which can significantly impact patient adherence and persistence to anticancer therapies. Oncology pharmacists play a crucial role in managing treatment-related toxicities and optimizing supportive care for HR+/HER2− mBC, serving as key resources for proactively monitoring, identifying, and managing these AEs. In addition to a review of specific AE profiles, this session will explore strategies for timely intervention and dose adjustments, effective patient counseling techniques to enhance adherence and self-management of toxicities, and the implementation of initiatives to optimize patient safety and outcomes.
Target audience: Oncology pharmacists

Type of activity: Application
Release date: July 24, 2025
Expiration date: July 24, 2026

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Develop tailored management plans to minimize and mitigate the adverse effects (AEs) of novel targeted therapies in HR+/HER2-negative (HER2−) metastatic breast cancer, focusing on proactive intervention and monitoring

2. Apply strategies for managing AEs of HR+/HER2− breast cancer therapies, including appropriate dose adjustments and supportive care interventions, to minimize treatment interruptions and enhance patient outcomes

3. Examine the key considerations for effective patient counseling, including AE profiles, dosing, and administration schedules, to improve treatment outcomes and patient understanding in HR+/HER2− metastatic breast cancer